Intranasal Oxytocin Blocks Alcohol Withdrawal in Human Subjects
Background The neuropeptide, oxytocin (OT), has been reported to block tolerance formation to alcohol and decrease withdrawal symptoms in alcohol‐dependent rodents. Numerous recent studies in human subjects indicate that OT administered by the intranasal route penetrates into and exerts effects with...
Gespeichert in:
| Veröffentlicht in: | Alcoholism, clinical and experimental research Jg. 37; H. 3; S. 484 - 489 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
England
Blackwell Publishing Ltd
01.03.2013
|
| Schlagworte: | |
| ISSN: | 0145-6008, 1530-0277, 1530-0277 |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Background
The neuropeptide, oxytocin (OT), has been reported to block tolerance formation to alcohol and decrease withdrawal symptoms in alcohol‐dependent rodents. Numerous recent studies in human subjects indicate that OT administered by the intranasal route penetrates into and exerts effects within the brain.
Methods
In a randomized, double‐blind clinical trial, intranasal OT (24 IU/dose, N = 7) or placebo (N = 4) was given twice daily for 3 days in alcohol‐dependent subjects admitted to a research unit for medical detoxification using Clinical Institute Withdrawal Assessment for Alcohol (CIWA) score‐driven PRN administration of lorazepam. Subjects rated themselves on the Alcohol Withdrawal Symptom Checklist (AWSC) each time CIWA scores were obtained. Subjects also completed the Penn Alcohol Craving Scale, an Alcohol Craving Visual Analog Scale (ACVAS) and the Profile of Mood States (POMS) on inpatient days 2 and 3.
Results
All subjects had drunk heavily each day for at least 2 weeks prior to study and had previously experienced withdrawal upon stopping/decreasing alcohol consumption. OT was superior to placebo in reducing alcohol withdrawal as evidenced by: less total lorazepam required to complete detoxification (3.4 mg [4.7, SD] vs. 16.5 [4.4], p = 0.0015), lower mean CIWA scores on admission day 1 (4.3 [2.3] vs. 11.8 [0.4], p < 0.0001) and day 2 (3.4 [2.2] vs. 11.1 [3.6], p < 0.002), lower AWSC scores on days 1 and 2 (p < 0.02; p = 0.07), and lower ACVAS ratings (p = 0.01) and lower POMS Tension/Anxiety subscale scores on day 2 (p < 0.01).
Conclusions
This is the first demonstration that OT treatment may block alcohol withdrawal in human subjects. Our results are consistent with previous findings in rodents that OT inhibits neuroadaptation to and withdrawal from alcohol. OT could have advantages over benzodiazepines in managing alcohol withdrawal because it may reverse rather than maintain sedative‐hypnotic tolerance. It will be important to test whether OT treatment is effective in reducing drinking in alcohol‐dependent outpatients. |
|---|---|
| AbstractList | The neuropeptide, oxytocin (OT), has been reported to block tolerance formation to alcohol and decrease withdrawal symptoms in alcohol-dependent rodents. Numerous recent studies in human subjects indicate that OT administered by the intranasal route penetrates into and exerts effects within the brain.BACKGROUNDThe neuropeptide, oxytocin (OT), has been reported to block tolerance formation to alcohol and decrease withdrawal symptoms in alcohol-dependent rodents. Numerous recent studies in human subjects indicate that OT administered by the intranasal route penetrates into and exerts effects within the brain.In a randomized, double-blind clinical trial, intranasal OT (24 IU/dose, N = 7) or placebo (N = 4) was given twice daily for 3 days in alcohol-dependent subjects admitted to a research unit for medical detoxification using Clinical Institute Withdrawal Assessment for Alcohol (CIWA) score-driven PRN administration of lorazepam. Subjects rated themselves on the Alcohol Withdrawal Symptom Checklist (AWSC) each time CIWA scores were obtained. Subjects also completed the Penn Alcohol Craving Scale, an Alcohol Craving Visual Analog Scale (ACVAS) and the Profile of Mood States (POMS) on inpatient days 2 and 3.METHODSIn a randomized, double-blind clinical trial, intranasal OT (24 IU/dose, N = 7) or placebo (N = 4) was given twice daily for 3 days in alcohol-dependent subjects admitted to a research unit for medical detoxification using Clinical Institute Withdrawal Assessment for Alcohol (CIWA) score-driven PRN administration of lorazepam. Subjects rated themselves on the Alcohol Withdrawal Symptom Checklist (AWSC) each time CIWA scores were obtained. Subjects also completed the Penn Alcohol Craving Scale, an Alcohol Craving Visual Analog Scale (ACVAS) and the Profile of Mood States (POMS) on inpatient days 2 and 3.All subjects had drunk heavily each day for at least 2 weeks prior to study and had previously experienced withdrawal upon stopping/decreasing alcohol consumption. OT was superior to placebo in reducing alcohol withdrawal as evidenced by: less total lorazepam required to complete detoxification (3.4 mg [4.7, SD] vs. 16.5 [4.4], p = 0.0015), lower mean CIWA scores on admission day 1 (4.3 [2.3] vs. 11.8 [0.4], p < 0.0001) and day 2 (3.4 [2.2] vs. 11.1 [3.6], p < 0.002), lower AWSC scores on days 1 and 2 (p < 0.02; p = 0.07), and lower ACVAS ratings (p = 0.01) and lower POMS Tension/Anxiety subscale scores on day 2 (p < 0.01).RESULTSAll subjects had drunk heavily each day for at least 2 weeks prior to study and had previously experienced withdrawal upon stopping/decreasing alcohol consumption. OT was superior to placebo in reducing alcohol withdrawal as evidenced by: less total lorazepam required to complete detoxification (3.4 mg [4.7, SD] vs. 16.5 [4.4], p = 0.0015), lower mean CIWA scores on admission day 1 (4.3 [2.3] vs. 11.8 [0.4], p < 0.0001) and day 2 (3.4 [2.2] vs. 11.1 [3.6], p < 0.002), lower AWSC scores on days 1 and 2 (p < 0.02; p = 0.07), and lower ACVAS ratings (p = 0.01) and lower POMS Tension/Anxiety subscale scores on day 2 (p < 0.01).This is the first demonstration that OT treatment may block alcohol withdrawal in human subjects. Our results are consistent with previous findings in rodents that OT inhibits neuroadaptation to and withdrawal from alcohol. OT could have advantages over benzodiazepines in managing alcohol withdrawal because it may reverse rather than maintain sedative-hypnotic tolerance. It will be important to test whether OT treatment is effective in reducing drinking in alcohol-dependent outpatients.CONCLUSIONSThis is the first demonstration that OT treatment may block alcohol withdrawal in human subjects. Our results are consistent with previous findings in rodents that OT inhibits neuroadaptation to and withdrawal from alcohol. OT could have advantages over benzodiazepines in managing alcohol withdrawal because it may reverse rather than maintain sedative-hypnotic tolerance. It will be important to test whether OT treatment is effective in reducing drinking in alcohol-dependent outpatients. The neuropeptide, oxytocin (OT), has been reported to block tolerance formation to alcohol and decrease withdrawal symptoms in alcohol-dependent rodents. Numerous recent studies in human subjects indicate that OT administered by the intranasal route penetrates into and exerts effects within the brain. In a randomized, double-blind clinical trial, intranasal OT (24 IU/dose, N = 7) or placebo (N = 4) was given twice daily for 3 days in alcohol-dependent subjects admitted to a research unit for medical detoxification using Clinical Institute Withdrawal Assessment for Alcohol (CIWA) score-driven PRN administration of lorazepam. Subjects rated themselves on the Alcohol Withdrawal Symptom Checklist (AWSC) each time CIWA scores were obtained. Subjects also completed the Penn Alcohol Craving Scale, an Alcohol Craving Visual Analog Scale (ACVAS) and the Profile of Mood States (POMS) on inpatient days 2 and 3. All subjects had drunk heavily each day for at least 2 weeks prior to study and had previously experienced withdrawal upon stopping/decreasing alcohol consumption. OT was superior to placebo in reducing alcohol withdrawal as evidenced by: less total lorazepam required to complete detoxification (3.4 mg [4.7, SD] vs. 16.5 [4.4], p = 0.0015), lower mean CIWA scores on admission day 1 (4.3 [2.3] vs. 11.8 [0.4], p < 0.0001) and day 2 (3.4 [2.2] vs. 11.1 [3.6], p < 0.002), lower AWSC scores on days 1 and 2 (p < 0.02; p = 0.07), and lower ACVAS ratings (p = 0.01) and lower POMS Tension/Anxiety subscale scores on day 2 (p < 0.01). This is the first demonstration that OT treatment may block alcohol withdrawal in human subjects. Our results are consistent with previous findings in rodents that OT inhibits neuroadaptation to and withdrawal from alcohol. OT could have advantages over benzodiazepines in managing alcohol withdrawal because it may reverse rather than maintain sedative-hypnotic tolerance. It will be important to test whether OT treatment is effective in reducing drinking in alcohol-dependent outpatients. Background The neuropeptide, oxytocin (OT), has been reported to block tolerance formation to alcohol and decrease withdrawal symptoms in alcohol‐dependent rodents. Numerous recent studies in human subjects indicate that OT administered by the intranasal route penetrates into and exerts effects within the brain. Methods In a randomized, double‐blind clinical trial, intranasal OT (24 IU/dose, N = 7) or placebo (N = 4) was given twice daily for 3 days in alcohol‐dependent subjects admitted to a research unit for medical detoxification using Clinical Institute Withdrawal Assessment for Alcohol (CIWA) score‐driven PRN administration of lorazepam. Subjects rated themselves on the Alcohol Withdrawal Symptom Checklist (AWSC) each time CIWA scores were obtained. Subjects also completed the Penn Alcohol Craving Scale, an Alcohol Craving Visual Analog Scale (ACVAS) and the Profile of Mood States (POMS) on inpatient days 2 and 3. Results All subjects had drunk heavily each day for at least 2 weeks prior to study and had previously experienced withdrawal upon stopping/decreasing alcohol consumption. OT was superior to placebo in reducing alcohol withdrawal as evidenced by: less total lorazepam required to complete detoxification (3.4 mg [4.7, SD] vs. 16.5 [4.4], p = 0.0015), lower mean CIWA scores on admission day 1 (4.3 [2.3] vs. 11.8 [0.4], p < 0.0001) and day 2 (3.4 [2.2] vs. 11.1 [3.6], p < 0.002), lower AWSC scores on days 1 and 2 (p < 0.02; p = 0.07), and lower ACVAS ratings (p = 0.01) and lower POMS Tension/Anxiety subscale scores on day 2 (p < 0.01). Conclusions This is the first demonstration that OT treatment may block alcohol withdrawal in human subjects. Our results are consistent with previous findings in rodents that OT inhibits neuroadaptation to and withdrawal from alcohol. OT could have advantages over benzodiazepines in managing alcohol withdrawal because it may reverse rather than maintain sedative‐hypnotic tolerance. It will be important to test whether OT treatment is effective in reducing drinking in alcohol‐dependent outpatients. |
| Author | Jarskog, Lars Fredrik Casey, Robin L. Garbutt, James C. Leserman, Jane Rau, Shane W. Fender, Trace Smedley, Kelly L. Kampov-Polevoi, Alexei Pedersen, Cort A. |
| AuthorAffiliation | 1 Department of Psychiatry, The University of North Carolina at Chapel Hill, Chapel Hill, NC 2 Department of Neurobiology Curriculum, The University of North Carolina at Chapel Hill, Chapel Hill, NC 4 North Carolina Psychiatric Research Center, Raleigh, NC 3 Bowles Center for Alcohol Studies The University of North Carolina at Chapel Hill, Chapel Hill, NC |
| AuthorAffiliation_xml | – name: 3 Bowles Center for Alcohol Studies The University of North Carolina at Chapel Hill, Chapel Hill, NC – name: 2 Department of Neurobiology Curriculum, The University of North Carolina at Chapel Hill, Chapel Hill, NC – name: 1 Department of Psychiatry, The University of North Carolina at Chapel Hill, Chapel Hill, NC – name: 4 North Carolina Psychiatric Research Center, Raleigh, NC |
| Author_xml | – sequence: 1 givenname: Cort A. surname: Pedersen fullname: Pedersen, Cort A. email: cort_pedersen@med.unc.edu organization: Department of Psychiatry, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina – sequence: 2 givenname: Kelly L. surname: Smedley fullname: Smedley, Kelly L. organization: Department of Psychiatry, The University of North Carolina at Chapel Hill, North Carolina, Chapel Hill – sequence: 3 givenname: Jane surname: Leserman fullname: Leserman, Jane organization: Department of Psychiatry, The University of North Carolina at Chapel Hill, North Carolina, Chapel Hill – sequence: 4 givenname: Lars Fredrik surname: Jarskog fullname: Jarskog, Lars Fredrik organization: Department of Psychiatry, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina – sequence: 5 givenname: Shane W. surname: Rau fullname: Rau, Shane W. organization: Department of Psychiatry, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina – sequence: 6 givenname: Alexei surname: Kampov-Polevoi fullname: Kampov-Polevoi, Alexei organization: Department of Psychiatry, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina – sequence: 7 givenname: Robin L. surname: Casey fullname: Casey, Robin L. organization: Department of Psychiatry, The University of North Carolina at Chapel Hill, North Carolina, Chapel Hill – sequence: 8 givenname: Trace surname: Fender fullname: Fender, Trace organization: Department of Psychiatry, The University of North Carolina at Chapel Hill, North Carolina, Chapel Hill – sequence: 9 givenname: James C. surname: Garbutt fullname: Garbutt, James C. organization: Department of Psychiatry, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23025690$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkVtP3DAQha2KqizQv1DlsS9Jx3F8yUur7YoCKioVF_E4chxv14s3hjgpu_--SVm2lycsSx7pzHxn5HNA9prQWEISChkdzodlRjmDFHIpsxxongEtucrWr8hkJ-yRCdCCpwJA7ZODGJcAUCgh3pD9nEHORQkT8ums6Vrd6Kh9crHedMG4Jvnsg7mLydSbsAg-uXXdom7149AyiKf9SjfJVV8treniEXk91z7at9v3kNx8Ob6enabnFydns-l5anhBVVpWulbKwlzVTNZSFTyX3JSKKgOMV9JqVUmQlbK1mA9XcWG4MkLavJZ1wdkh-fjEve-rla2NHdf2eN-6lW43GLTDf5XGLfBH-ImMcynECHi_BbThobexw5WLxnqvGxv6iJTRgjEhqRxa3_3ttTN5_rU_y5g2xNjaORrX6c6F0dp5pIBjTLjEMQ0c08AxJvwdE64HgPoP8OzxgtGt96PzdvPiOZzOji_HcgCkTwAXO7veAXR7h0IyyfH22wmKmbosufiOX9kv3cS5Kg |
| CitedBy_id | crossref_primary_10_3390_ijms22052372 crossref_primary_10_3389_fpsyg_2020_590051 crossref_primary_10_1093_ijnp_pyu009 crossref_primary_10_1016_j_drugalcdep_2019_01_003 crossref_primary_10_1111_adb_12893 crossref_primary_10_1016_j_yfrne_2016_08_001 crossref_primary_10_1152_physrev_00031_2017 crossref_primary_10_4155_tde_2018_0002 crossref_primary_10_3390_ijms22052405 crossref_primary_10_1016_j_neuropharm_2017_04_028 crossref_primary_10_1210_js_2019_00004 crossref_primary_10_1007_s00213_025_06779_x crossref_primary_10_1016_j_phrs_2022_106281 crossref_primary_10_1038_s41386_021_01046_x crossref_primary_10_1038_npp_2017_257 crossref_primary_10_12688_f1000research_7645_1 crossref_primary_10_63096_medtigo30612312 crossref_primary_10_15626_MP_2018_872 crossref_primary_10_1016_j_cct_2023_107084 crossref_primary_10_1007_s11920_016_0709_y crossref_primary_10_1016_j_neuropharm_2021_108567 crossref_primary_10_1016_j_neuroscience_2019_04_006 crossref_primary_10_1016_j_biopsych_2022_02_011 crossref_primary_10_1111_acer_13814 crossref_primary_10_1016_j_psychres_2021_114340 crossref_primary_10_1016_j_neubiorev_2021_06_009 crossref_primary_10_1016_j_pbb_2015_10_014 crossref_primary_10_1016_j_neuropharm_2017_04_032 crossref_primary_10_1111_bph_13757 crossref_primary_10_1080_14728214_2024_2342951 crossref_primary_10_1111_adb_12362 crossref_primary_10_1016_j_neulet_2016_10_066 crossref_primary_10_1097_FBP_0000000000000258 crossref_primary_10_1016_j_neubiorev_2018_08_014 crossref_primary_10_1093_ijnp_pyy025 crossref_primary_10_1016_j_physbeh_2016_06_009 crossref_primary_10_1111_ejn_70197 crossref_primary_10_1016_j_psyneuen_2016_09_018 crossref_primary_10_1016_j_biopsych_2015_05_013 crossref_primary_10_1016_j_pharmthera_2021_107820 crossref_primary_10_1002_hbm_23308 crossref_primary_10_1038_s41386_020_0719_7 crossref_primary_10_1016_j_psychres_2017_12_003 crossref_primary_10_1073_pnas_1416900112 crossref_primary_10_1016_j_euroneuro_2014_06_005 crossref_primary_10_1016_j_euroneuro_2021_04_015 crossref_primary_10_1016_j_tins_2017_10_003 crossref_primary_10_1016_j_coph_2017_08_009 crossref_primary_10_1016_j_neubiorev_2016_04_006 crossref_primary_10_1038_s41398_024_02993_x crossref_primary_10_1016_j_brainres_2014_01_050 crossref_primary_10_1007_s40429_021_00403_6 crossref_primary_10_1111_adb_12349 crossref_primary_10_1210_clinem_dgac015 crossref_primary_10_1111_acer_13430 crossref_primary_10_1073_pnas_1406324111 crossref_primary_10_1080_14656566_2021_1892641 crossref_primary_10_1016_j_neuropharm_2018_11_011 crossref_primary_10_1038_s41398_024_03076_7 crossref_primary_10_1093_alcalc_agaa133 crossref_primary_10_3389_fphar_2018_00177 crossref_primary_10_1016_j_pharmthera_2017_11_007 crossref_primary_10_1016_j_neubiorev_2023_105185 crossref_primary_10_1111_adb_70060 crossref_primary_10_1002_cne_24116 crossref_primary_10_1016_j_jphs_2025_04_004 crossref_primary_10_3389_fpubh_2017_00239 crossref_primary_10_1016_j_brainres_2020_146761 crossref_primary_10_1016_j_jgyn_2016_05_002 crossref_primary_10_3389_fpsyg_2014_01529 crossref_primary_10_1002_brb3_1749 crossref_primary_10_1159_000485563 crossref_primary_10_1007_s40263_016_0313_z crossref_primary_10_1371_journal_pbio_2006421 crossref_primary_10_1016_j_pbb_2017_08_012 crossref_primary_10_1016_j_jpsychires_2017_12_014 crossref_primary_10_1016_j_psychres_2015_05_039 crossref_primary_10_1111_jnc_15730 crossref_primary_10_1016_j_physbeh_2017_07_021 crossref_primary_10_3109_16066359_2016_1173682 crossref_primary_10_3389_fpsyg_2016_01436 crossref_primary_10_1080_15569543_2019_1619085 crossref_primary_10_1111_nyas_13140 crossref_primary_10_1007_s40211_017_0229_y crossref_primary_10_1007_s40501_019_00171_1 crossref_primary_10_1038_s41398_022_02161_z crossref_primary_10_1038_s41398_020_0714_0 crossref_primary_10_1097_ADM_0000000000000213 crossref_primary_10_1523_JNEUROSCI_3509_14_2014 crossref_primary_10_1038_s41386_022_01490_3 crossref_primary_10_1111_bph_15617 crossref_primary_10_1016_j_pharmthera_2020_107573 crossref_primary_10_3390_biom13030405 crossref_primary_10_1007_s40263_013_0137_z crossref_primary_10_1080_13543784_2018_1502269 crossref_primary_10_1093_scan_nsy027 crossref_primary_10_1016_j_brainresbull_2016_10_005 crossref_primary_10_1016_j_alcohol_2024_10_002 crossref_primary_10_1016_j_physbeh_2015_08_018 crossref_primary_10_1016_j_psyneuen_2019_104385 crossref_primary_10_3389_fpsyt_2018_00633 crossref_primary_10_1016_j_addicn_2022_100011 crossref_primary_10_1016_j_biopsych_2016_11_011 crossref_primary_10_1093_alcalc_agaf042 crossref_primary_10_1016_j_psychres_2015_07_064 crossref_primary_10_1111_acer_14217 crossref_primary_10_1016_j_brainres_2014_01_025 crossref_primary_10_3389_fphar_2022_927703 crossref_primary_10_1016_j_euroneuro_2021_10_577 crossref_primary_10_1371_journal_pone_0228700 crossref_primary_10_3389_fnbeh_2014_00360 crossref_primary_10_1016_j_biopsych_2022_12_003 crossref_primary_10_1007_s00115_013_3832_6 crossref_primary_10_1016_j_pbb_2018_11_008 crossref_primary_10_1016_j_psyneuen_2017_07_481 crossref_primary_10_1016_j_jpsychires_2025_04_007 crossref_primary_10_3390_brainsci13081206 crossref_primary_10_3390_ijms23179940 crossref_primary_10_1007_s00213_020_05741_3 crossref_primary_10_1007_s00406_020_01115_0 crossref_primary_10_1016_j_cct_2019_05_002 crossref_primary_10_1124_pharmrev_120_000083 crossref_primary_10_1111_dar_13591 crossref_primary_10_1111_acer_13359 crossref_primary_10_1016_j_neuroscience_2013_08_048 crossref_primary_10_1016_j_bmc_2017_11_001 crossref_primary_10_1111_acer_12147 crossref_primary_10_1016_j_jpsychires_2022_06_011 crossref_primary_10_1210_jendso_bvae198 crossref_primary_10_1517_17425247_2015_1069815 crossref_primary_10_1016_j_neubiorev_2017_05_017 crossref_primary_10_3389_fpsyt_2022_842609 crossref_primary_10_1016_j_neubiorev_2019_10_012 crossref_primary_10_1016_j_neuropharm_2020_108091 crossref_primary_10_1136_bmjopen_2021_059672 |
| Cites_doi | 10.1001/archinte.162.10.1117 10.1016/j.amjmed.2006.03.015 10.1016/0196-9781(85)90067-1 10.1210/endo.138.7.5255 10.1016/j.neuron.2008.04.009 10.1016/j.biopsych.2006.07.015 10.1016/0091-3057(91)90549-H 10.1016/S0272-7358(99)00027-6 10.1038/nature03701 10.1016/S0306-4530(98)00064-X 10.1111/j.1530-0277.2007.00445.x 10.1016/S0031-9384(96)00212-0 10.1111/j.1360-0443.1988.tb00485.x 10.1152/physrev.2001.81.2.629 10.1016/j.biopsych.2010.04.039 10.1073/pnas.0910249107 10.1111/j.1530-0277.2007.00345.x 10.1016/S0025-7125(05)70554-X 10.1038/nn0602-849 10.1210/en.2002-0197 10.1111/j.1530-0277.1999.tb04349.x 10.3109/10673220903523615 10.1111/j.1360-0443.1989.tb00737.x 10.1016/j.psyneuen.2009.06.016 10.1016/j.schres.2011.07.027 10.1007/s00213-005-0293-z 10.1016/0741-8329(85)90082-5 10.1111/j.1530-0277.2009.00986.x 10.1016/0196-9781(92)90010-Z 10.1016/j.biopsych.2007.06.026 10.1016/S0091-3057(80)80043-8 10.1016/0006-3223(96)00120-5 10.1111/j.0953-8194.2004.01161.x 10.1016/S0006-3223(03)00465-7 10.1523/JNEUROSCI.21-07-02546.2001 10.1016/j.biopsych.2007.03.025 10.1177/0269881111400642 10.1523/JNEUROSCI.3984-05.2005 10.1001/jama.1997.03550020076042 |
| ContentType | Journal Article |
| Copyright | Copyright © 2012 by the Research Society on Alcoholism Copyright © 2012 by the Research Society on Alcoholism. |
| Copyright_xml | – notice: Copyright © 2012 by the Research Society on Alcoholism – notice: Copyright © 2012 by the Research Society on Alcoholism. |
| DBID | BSCLL AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM |
| DOI | 10.1111/j.1530-0277.2012.01958.x |
| DatabaseName | Istex CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Social Welfare & Social Work |
| EISSN | 1530-0277 |
| EndPage | 489 |
| ExternalDocumentID | PMC3557665 23025690 10_1111_j_1530_0277_2012_01958_x ACER1958 ark_67375_WNG_6C8R956P_K |
| Genre | article Randomized Controlled Trial Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: National Center for Research Resources funderid: UL1RR025747 – fundername: National Institute of Alcohol Abuse and Alcoholism funderid: 5‐P60‐AA011605‐08‐13 – fundername: NIAAA NIH HHS grantid: 5-P60-AA011605-08-13 – fundername: NCRR NIH HHS grantid: UL1RR025747 – fundername: NIAAA NIH HHS grantid: P60 AA011605 – fundername: NCRR NIH HHS grantid: UL1 RR025747 – fundername: National Center for Research Resources : NCRR grantid: UL1 RR025747 || RR – fundername: National Institute on Alcohol Abuse and Alcoholism : NIAAA grantid: P60 AA011605 || AA |
| GroupedDBID | --- -ET -~X .3N .55 .GA .Y3 05W 08G 0R~ 10A 1OB 1OC 23M 31~ 33P 36B 3SF 4.4 4Q1 4Q2 4Q3 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 6J9 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 A8Z AAESR AAEVG AAHQN AAIPD AAKAS AAMNL AANHP AANLZ AAONW AASGY AAWTL AAXRX AAYCA AAZKR ABCQN ABCUV ABEML ABIVO ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCZN ACFBH ACGFO ACGFS ACMXC ACPOU ACPRK ACRPL ACSCC ACXBN ACXQS ACYXJ ADBBV ADBIZ ADBTR ADEOM ADIZJ ADKYN ADMGS ADNMO ADOZA ADZCM ADZMN AEGXH AEIGN AEIMD AEUYR AFBPY AFFPM AFGKR AFRAH AFTRI AFUWQ AFWVQ AFZJQ AGQPQ AGYGG AHBTC AHEFC AHMBA AHRYX AI. AIACR AIAGR AIQQE AITYG AIURR AIZYK ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BSCLL BY8 BYPQX C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DUUFO EBD EBS EJD EMB EMOBN ESTFP EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IX1 J0M K48 KBYEO KMI L89 LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NTWIH O66 O9- OAG OAH OIG OL1 OMB OPX OVD OWU OWV OWW OWX OWY OWZ P2P P2W P2X P2Z P4B P4D PALCI PQQKQ Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SAMSI SJN SUPJJ SV3 TEORI TWZ UAP UB1 VH1 VVN W8V W99 WBKPD WHWMO WIH WIJ WIK WOHZO WOQ WOW WQJ WVDHM WXI WXSBR X7M XG1 XSW XYM YFH ZFV ZGI ZZTAW ~IA ~WT AAYXX ABUFD CITATION O8X CGR CUY CVF ECM EIF NPM 7X8 5PM |
| ID | FETCH-LOGICAL-c5418-9bad88e0f8d37d7845275c9818c035b7ea8b707b8ed6fd6f856c58c67e2d7d453 |
| IEDL.DBID | DRFUL |
| ISICitedReferencesCount | 156 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000315500600015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0145-6008 1530-0277 |
| IngestDate | Tue Nov 04 01:56:54 EST 2025 Sun Nov 09 10:22:41 EST 2025 Mon Jul 21 05:43:46 EDT 2025 Sat Nov 29 05:28:53 EST 2025 Tue Nov 18 21:50:33 EST 2025 Sun Sep 21 06:21:41 EDT 2025 Sun Sep 21 06:16:59 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 3 |
| Language | English |
| License | http://onlinelibrary.wiley.com/termsAndConditions#vor Copyright © 2012 by the Research Society on Alcoholism. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5418-9bad88e0f8d37d7845275c9818c035b7ea8b707b8ed6fd6f856c58c67e2d7d453 |
| Notes | Data S1. Modified Clinical Institute Withdrawal Assessment for Alcohol. ark:/67375/WNG-6C8R956P-K National Institute of Alcohol Abuse and Alcoholism - No. 5-P60-AA011605-08-13 ArticleID:ACER1958 National Center for Research Resources - No. UL1RR025747 istex:937EA4D3A266A78D49F6A2B06C848BA38621D359 ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/3557665 |
| PMID | 23025690 |
| PQID | 1314336717 |
| PQPubID | 23479 |
| PageCount | 6 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_3557665 proquest_miscellaneous_1314336717 pubmed_primary_23025690 crossref_citationtrail_10_1111_j_1530_0277_2012_01958_x crossref_primary_10_1111_j_1530_0277_2012_01958_x wiley_primary_10_1111_j_1530_0277_2012_01958_x_ACER1958 istex_primary_ark_67375_WNG_6C8R956P_K |
| PublicationCentury | 2000 |
| PublicationDate | March 2013 |
| PublicationDateYYYYMMDD | 2013-03-01 |
| PublicationDate_xml | – month: 03 year: 2013 text: March 2013 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Alcoholism, clinical and experimental research |
| PublicationTitleAlternate | Alcohol Clin Exp Res |
| PublicationYear | 2013 |
| Publisher | Blackwell Publishing Ltd |
| Publisher_xml | – name: Blackwell Publishing Ltd |
| References | Flannery BA, Volpicelli JR, Pettinati HM (1999) Psychometric properties of the Penn Alcohol Craving Scale. Alcohol Clin Exp Res 23:1289-1295. Szabó G, Kovács GL, Telegdy G (1988) Brain monoamines are involved in mediating the action of neurohypophyseal peptide hormones on ethanol tolerance. Acta Physiol Hung 71:459-466. Domes G, Lischke A, Berger C, Grossmann A, Hauenstein K, Heinrichs M, Herpertz SC (2010) Effects of intranasal oxytocin on emotional face processing in women. Psychoneuroendocrinology 35:83-93. MacDonald K, MacDonald TM (2010) The peptide that binds: a systematic review of oxytocin and its prosocial effects in humans. Harv Rev Psychiatry 18:1-21. Szabó G, Kovács GL, Telegdy G (1989) Intraventricular administration of neurohypophyseal hormones interferes with the development of tolerance to ethanol. Acta Physiol Hung 73:97-103. Ring RH, Malberg JE, Potestio L, Ping J, Boikess S, Luo B, Schechter LE, Rizzo S, Rahman Z, Rosensweig-Lipson S (2006) Anxiolytic-like activity of oxytocin in male mice: behavioral and autonomic evidence, therapeutic implications. Psychopharmacology 185:218-225. Saitz R, O'Malley SS (1997) Pharmacotherapies for alcohol abuse. Withdrawal and treatment. Med Clin North Am 81:881-907. Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM (1989) Assessment of alcohol withdrawal: the revised Clinical Institute Withdrawal Assessment of Alcohol Scale (CIWA-Ar). Br J Addict 84:1353-1357. Heinrichs M, Baumgartner T, Kirschbaum C, Ehlert U (2003) Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress. Biol Psychiatry 54:1389-1398. Kushner MG, Abrams K, Borchardt C (2000) The relationship between anxiety disorders and alcohol use disorders: a review of major perspectives and findings. Clin Psychol Rev 20:149-171. Szabó G, Kovács GL, Telegdy G (1987) Effects of neurohypophyseal peptide hormones on alcohol dependence and withdrawal. Alcohol Alcohol 22:71-74. Pedersen CA, Gibson CM, Rau SW, Salimi K, Smedley KL, Casey RL, Leserman J, Jarskog LF, Penn DL (2011) Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia. Schizophr Res 132:50-53. Feifel D, MacDonald K, Nguyen A, Cobb P, Warlan H, Galangue B, Minassian A, Becker O, Cooper J, Perry W, Lefebvre M, Gonzales J, Hadley A (2010) Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol Psychiatry 68:678-680. Windle RJ, Shanks N, Lightman SL, Ingram CD (1997) Central oxytocin administration reduces stress-induced corticosterone release and anxiety behavior in rats. Endocrinology 138:2829-2834. den Boer JA, Westenberg HG (1992) Oxytocin in obsessive compulsive disorder. Peptides 13:1083-1085. Lee H-J, Macbeth AH, Pagani JH, Young WS III (2009) Oxytocin: the great facilitator of life. Prog Neurobiol 88:127-151. Mantella RC, Vollmer RR, Li X, Amico JA (2003) Female oxytocin-deficient mice display enhanced anxiety-related behavior. Endocrinology 144:2291-2296. Pittman B, Gueorguieva F, Krupitsky E, Rudenko AA, Flannery BA, Krystal JH (2007) Multidimensionality of the Alcohol Withdrawal Symptom Checklist: a factor analysis of the Alcohol Withdrawal Symptom Checklist and CIWA-Ar. Alcohol Clin Exp Res 31:612-618. Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL (2002) Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 5:514-516. Breese GR, Knapp DJ, Overstreet DH (2004) Stress sensitization of ethanol withdrawal-induced reduction in social interaction: inhibition by CRF-1 and benzodiazepine receptor antagonist and a 5-HT1A-receptor agonist. Neuropsychopharmacology 178:367-380. Domes G, Heinrichs M, Michel A, Berger C, Herpertz SC (2007b) Oxytocin improves "mind-reading" in humans. Biol Psychiatry 61:731-733. Rigter H, Dortmans C, Crabbe JC Jr (1980) Effects of peptides related to neurohypophyseal hormones on ethanol tolerance. Pharmacol Biochem Behav 13:285-290. Gimpl G, Fahrenholz F (2001) The oxytocin receptor system: structure, function, and regulation. Physiol Rev 81:629-683. Bale TL, Davis AM, Auger AP, Dorsa DM, McCarthy MM (2001) CNS region-specific oxytocin receptor expression: importance in regulation of anxiety and sex behavior. J Neurosci 21:2546-2552. Andari E, Duhamel J-R, Zalla T, Herbrecht E, Leboyer M, Sirigu A (2010) Promoting social behavior with oxytocin in high-functioning autism spectrum disorders. Proc Natl Acad Sci U S A 107:4389-4394. de Oliveira DC, Zuardi AW, Graeff FG, Queiroz RH, Crippa JA (2011) Anxiolytic-like effect of oxytocin in the simulated public speaking test. J Psychopharmacol 26:497-504. Saitz R (2007) Baclofen for alcohol withdrawal: not comparable to the gold standard (benzodiazepines). Am J Med 120:e9. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC (1998) The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59:22-33. Kovács GL, Sarnyai Z, Szabó G (1998) Oxytocin and addiction: a review. Psychoneuroendocrinology 23:945-962. Overstreet DH, Knapp DJ, Breese GR (2007) Drug challenges reveal differences in mediation of stress facilitation of voluntary alcohol drinking and withdrawal-induced anxiety in alcohol-preferring P rats. Alcohol Clin Exp Res 31:1473-1481. Daeppen JB, Gache P, Landry U, Sekera E, Schweizer V, Gloor S, Yersin B (2002) Symptom-triggered vs. fixed-schedule doses of benzodiazepine for alcohol withdrawal: a randomized treatment trial. Arch Intern Med 162:1093-1094. Mayo-Smith MF (1997) Pharmacological management of alcohol withdrawal: a meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. JAMA 278:144-151. Sobell LC, Sobell MB, Leo GL, Cancilla A (1988) Reliability of a timeline followback method: assessing normal drinkers' reports of recent drinking and a comparative evaluation across several populations. Br J Addict 83:393-402. Domes G, Heinrichs M, Gläscher J, Büchel C, Braus DF, Herpertz SC (2007a) Oxytocin attenuates amygdala responses to emotional faces regardless of valence. Biol Psychiatry 62:1187-1190. Myrick H, Malcolm R, Randall PK, Boyle E, Anton RF, Becker HC, Randall CL (2009) A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal. Alcohol Clin Exp Res 33:1582-1588. McNair DM, Lorr M, Droppleman LF (1971) EDITS Manual for the Profile of Mood States. Educational and Industrial Testing Service, San Diego, CA. Vadlamudi S, Pedersen CA, Amico JA, Breese GR, Knapp D (2004) Neuroadaptation to alcohol and morphine is altered in oxytocin knockout mice. Society for Neuroscience Annual Meeting, Washington, DC. Abstract #577.12. Baumgartner T, Heinrichs M, Vonlanthen A, Fischbacher U, Fehr E (2008) Oxytocin shapes the neural circuitry of trust and trust adaptation in humans. Neuron 58:639-650. McCarthy MM, McDonald CH, Brooks PJ, Goldman D (1996) An anxiolytic action of oxytocin is enhanced by estrogen in the mouse. Physiol Behav 60:1209-1215. Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E (2005) Oxytocin increases trust in humans. Nature 435:673-676. Guastella AJ, Mitchell PB, Dadds MR (2008) Oxytocin increases gaze to the eye region of human faces. Biol Psychiatry 63:3-5. Szabó G, Kovács GL, Székeki S, Telegdy G (1985) The effects of neurohypophyseal hormones on tolerance to the hypothermic effect of ethanol. Alcohol 2:567-574. Jodogne C, Tirelli E, Klingbiel P, Legros JJ (1991) Oxytocin attenuates tolerance not only to the hypothermic but also to the myorelaxant and akinesic effects of ethanol in mice. Pharmacol Biochem Behav 40:261-265. Amico JA, Mantella RC, Vollmer RR, Li X (2004) Anxiety and stress responses in female oxytocin deficient mice. J Neuroendocrinol 16:319-324. Epperson CN, McDougle CJ, Price LH (1996) Intranasal oxytocin in obsessive-compulsive disorder. Biol Psychiatry 40:547-549. Pucilowski O, Kotowski W, Trzaskowa E (1985) The effect of oxytocin and fragment (MIF-1) on the development of tolerance to hypothermic and hypnotic action of ethanol in the rat. Peptides 6:7-10. Kirsch P, Esslinger C, Chen Q, Mier D, Lis S, Siddhanti S, Gruppe H, Mattay VS, Gallhofer B, Meyer-Lindenberg A (2005) Oxytocin modulates neural circuitry for social cognition and fear in humans. J Neurosci 25:11489-11493. Knapp DJ, Overstreet DH, Hubka JC, Breese GR, Pedersen CA (2010) Inhibitory effects of oxytocin on anxiety-like behavior and alcohol consumption in P-rats subjected to repeated cycles of voluntary ethanol consumption and stress. Alcohol Clin Exp Res 34:145A. 2010; 34 1997; 278 1989; 84 2009; 88 1997; 138 2010; 35 1997; 81 2010; 107 2010; 18 1985; 2 2002; 5 2005; 435 2000; 20 1985; 6 2007; 120 2008; 58 1999; 23 1992; 13 1971 2004 2007; 31 1988; 71 1998; 23 2003; 54 2011; 132 2001; 21 2005; 25 2004; 178 1989; 73 2007b; 61 2001; 81 2009; 33 1998; 59 1987; 22 2010; 68 2004; 16 2002; 162 1980; 13 1991; 40 2007a; 62 2006; 185 1996; 60 1996; 40 1988; 83 2008; 63 2011; 26 2003; 144 e_1_2_6_32_1 e_1_2_6_10_1 e_1_2_6_31_1 Breese GR (e_1_2_6_8_1) 2004; 178 Szabó G (e_1_2_6_46_1) 1988; 71 e_1_2_6_19_1 e_1_2_6_13_1 e_1_2_6_36_1 Szabó G (e_1_2_6_47_1) 1989; 73 e_1_2_6_14_1 Knapp DJ (e_1_2_6_21_1) 2010; 34 e_1_2_6_35_1 e_1_2_6_11_1 e_1_2_6_34_1 e_1_2_6_12_1 e_1_2_6_33_1 e_1_2_6_17_1 e_1_2_6_18_1 e_1_2_6_39_1 Szabó G (e_1_2_6_45_1) 1987; 22 e_1_2_6_15_1 e_1_2_6_38_1 e_1_2_6_16_1 e_1_2_6_37_1 e_1_2_6_42_1 Vadlamudi S (e_1_2_6_48_1) 2004 e_1_2_6_43_1 e_1_2_6_20_1 e_1_2_6_40_1 Lee H‐J (e_1_2_6_25_1) 2009; 88 e_1_2_6_9_1 Sheehan DV (e_1_2_6_41_1) 1998; 59 e_1_2_6_5_1 e_1_2_6_4_1 e_1_2_6_7_1 e_1_2_6_6_1 e_1_2_6_24_1 e_1_2_6_49_1 e_1_2_6_3_1 e_1_2_6_23_1 e_1_2_6_2_1 e_1_2_6_22_1 McNair DM (e_1_2_6_30_1) 1971 e_1_2_6_29_1 e_1_2_6_44_1 e_1_2_6_28_1 e_1_2_6_27_1 e_1_2_6_26_1 23614612 - Alcohol Clin Exp Res. 2013 May;37(5):720-1 |
| References_xml | – reference: Domes G, Heinrichs M, Michel A, Berger C, Herpertz SC (2007b) Oxytocin improves "mind-reading" in humans. Biol Psychiatry 61:731-733. – reference: Szabó G, Kovács GL, Telegdy G (1987) Effects of neurohypophyseal peptide hormones on alcohol dependence and withdrawal. Alcohol Alcohol 22:71-74. – reference: Mayo-Smith MF (1997) Pharmacological management of alcohol withdrawal: a meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. JAMA 278:144-151. – reference: Windle RJ, Shanks N, Lightman SL, Ingram CD (1997) Central oxytocin administration reduces stress-induced corticosterone release and anxiety behavior in rats. Endocrinology 138:2829-2834. – reference: Amico JA, Mantella RC, Vollmer RR, Li X (2004) Anxiety and stress responses in female oxytocin deficient mice. J Neuroendocrinol 16:319-324. – reference: McCarthy MM, McDonald CH, Brooks PJ, Goldman D (1996) An anxiolytic action of oxytocin is enhanced by estrogen in the mouse. Physiol Behav 60:1209-1215. – reference: Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC (1998) The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59:22-33. – reference: Sullivan JT, Sykora K, Schneiderman J, Naranjo CA, Sellers EM (1989) Assessment of alcohol withdrawal: the revised Clinical Institute Withdrawal Assessment of Alcohol Scale (CIWA-Ar). Br J Addict 84:1353-1357. – reference: Andari E, Duhamel J-R, Zalla T, Herbrecht E, Leboyer M, Sirigu A (2010) Promoting social behavior with oxytocin in high-functioning autism spectrum disorders. Proc Natl Acad Sci U S A 107:4389-4394. – reference: Lee H-J, Macbeth AH, Pagani JH, Young WS III (2009) Oxytocin: the great facilitator of life. Prog Neurobiol 88:127-151. – reference: Mantella RC, Vollmer RR, Li X, Amico JA (2003) Female oxytocin-deficient mice display enhanced anxiety-related behavior. Endocrinology 144:2291-2296. – reference: Domes G, Lischke A, Berger C, Grossmann A, Hauenstein K, Heinrichs M, Herpertz SC (2010) Effects of intranasal oxytocin on emotional face processing in women. Psychoneuroendocrinology 35:83-93. – reference: Gimpl G, Fahrenholz F (2001) The oxytocin receptor system: structure, function, and regulation. Physiol Rev 81:629-683. – reference: Overstreet DH, Knapp DJ, Breese GR (2007) Drug challenges reveal differences in mediation of stress facilitation of voluntary alcohol drinking and withdrawal-induced anxiety in alcohol-preferring P rats. Alcohol Clin Exp Res 31:1473-1481. – reference: Sobell LC, Sobell MB, Leo GL, Cancilla A (1988) Reliability of a timeline followback method: assessing normal drinkers' reports of recent drinking and a comparative evaluation across several populations. Br J Addict 83:393-402. – reference: Kirsch P, Esslinger C, Chen Q, Mier D, Lis S, Siddhanti S, Gruppe H, Mattay VS, Gallhofer B, Meyer-Lindenberg A (2005) Oxytocin modulates neural circuitry for social cognition and fear in humans. J Neurosci 25:11489-11493. – reference: Myrick H, Malcolm R, Randall PK, Boyle E, Anton RF, Becker HC, Randall CL (2009) A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal. Alcohol Clin Exp Res 33:1582-1588. – reference: Born J, Lange T, Kern W, McGregor GP, Bickel U, Fehm HL (2002) Sniffing neuropeptides: a transnasal approach to the human brain. Nat Neurosci 5:514-516. – reference: MacDonald K, MacDonald TM (2010) The peptide that binds: a systematic review of oxytocin and its prosocial effects in humans. Harv Rev Psychiatry 18:1-21. – reference: Szabó G, Kovács GL, Székeki S, Telegdy G (1985) The effects of neurohypophyseal hormones on tolerance to the hypothermic effect of ethanol. Alcohol 2:567-574. – reference: McNair DM, Lorr M, Droppleman LF (1971) EDITS Manual for the Profile of Mood States. Educational and Industrial Testing Service, San Diego, CA. – reference: Rigter H, Dortmans C, Crabbe JC Jr (1980) Effects of peptides related to neurohypophyseal hormones on ethanol tolerance. Pharmacol Biochem Behav 13:285-290. – reference: Baumgartner T, Heinrichs M, Vonlanthen A, Fischbacher U, Fehr E (2008) Oxytocin shapes the neural circuitry of trust and trust adaptation in humans. Neuron 58:639-650. – reference: Vadlamudi S, Pedersen CA, Amico JA, Breese GR, Knapp D (2004) Neuroadaptation to alcohol and morphine is altered in oxytocin knockout mice. Society for Neuroscience Annual Meeting, Washington, DC. Abstract #577.12. – reference: Domes G, Heinrichs M, Gläscher J, Büchel C, Braus DF, Herpertz SC (2007a) Oxytocin attenuates amygdala responses to emotional faces regardless of valence. Biol Psychiatry 62:1187-1190. – reference: Saitz R, O'Malley SS (1997) Pharmacotherapies for alcohol abuse. Withdrawal and treatment. Med Clin North Am 81:881-907. – reference: Szabó G, Kovács GL, Telegdy G (1988) Brain monoamines are involved in mediating the action of neurohypophyseal peptide hormones on ethanol tolerance. Acta Physiol Hung 71:459-466. – reference: den Boer JA, Westenberg HG (1992) Oxytocin in obsessive compulsive disorder. Peptides 13:1083-1085. – reference: Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E (2005) Oxytocin increases trust in humans. Nature 435:673-676. – reference: Pedersen CA, Gibson CM, Rau SW, Salimi K, Smedley KL, Casey RL, Leserman J, Jarskog LF, Penn DL (2011) Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia. Schizophr Res 132:50-53. – reference: Pucilowski O, Kotowski W, Trzaskowa E (1985) The effect of oxytocin and fragment (MIF-1) on the development of tolerance to hypothermic and hypnotic action of ethanol in the rat. Peptides 6:7-10. – reference: Szabó G, Kovács GL, Telegdy G (1989) Intraventricular administration of neurohypophyseal hormones interferes with the development of tolerance to ethanol. Acta Physiol Hung 73:97-103. – reference: Saitz R (2007) Baclofen for alcohol withdrawal: not comparable to the gold standard (benzodiazepines). Am J Med 120:e9. – reference: Flannery BA, Volpicelli JR, Pettinati HM (1999) Psychometric properties of the Penn Alcohol Craving Scale. Alcohol Clin Exp Res 23:1289-1295. – reference: Jodogne C, Tirelli E, Klingbiel P, Legros JJ (1991) Oxytocin attenuates tolerance not only to the hypothermic but also to the myorelaxant and akinesic effects of ethanol in mice. Pharmacol Biochem Behav 40:261-265. – reference: Kovács GL, Sarnyai Z, Szabó G (1998) Oxytocin and addiction: a review. Psychoneuroendocrinology 23:945-962. – reference: Knapp DJ, Overstreet DH, Hubka JC, Breese GR, Pedersen CA (2010) Inhibitory effects of oxytocin on anxiety-like behavior and alcohol consumption in P-rats subjected to repeated cycles of voluntary ethanol consumption and stress. Alcohol Clin Exp Res 34:145A. – reference: Heinrichs M, Baumgartner T, Kirschbaum C, Ehlert U (2003) Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress. Biol Psychiatry 54:1389-1398. – reference: de Oliveira DC, Zuardi AW, Graeff FG, Queiroz RH, Crippa JA (2011) Anxiolytic-like effect of oxytocin in the simulated public speaking test. J Psychopharmacol 26:497-504. – reference: Pittman B, Gueorguieva F, Krupitsky E, Rudenko AA, Flannery BA, Krystal JH (2007) Multidimensionality of the Alcohol Withdrawal Symptom Checklist: a factor analysis of the Alcohol Withdrawal Symptom Checklist and CIWA-Ar. Alcohol Clin Exp Res 31:612-618. – reference: Ring RH, Malberg JE, Potestio L, Ping J, Boikess S, Luo B, Schechter LE, Rizzo S, Rahman Z, Rosensweig-Lipson S (2006) Anxiolytic-like activity of oxytocin in male mice: behavioral and autonomic evidence, therapeutic implications. Psychopharmacology 185:218-225. – reference: Guastella AJ, Mitchell PB, Dadds MR (2008) Oxytocin increases gaze to the eye region of human faces. Biol Psychiatry 63:3-5. – reference: Breese GR, Knapp DJ, Overstreet DH (2004) Stress sensitization of ethanol withdrawal-induced reduction in social interaction: inhibition by CRF-1 and benzodiazepine receptor antagonist and a 5-HT1A-receptor agonist. Neuropsychopharmacology 178:367-380. – reference: Daeppen JB, Gache P, Landry U, Sekera E, Schweizer V, Gloor S, Yersin B (2002) Symptom-triggered vs. fixed-schedule doses of benzodiazepine for alcohol withdrawal: a randomized treatment trial. Arch Intern Med 162:1093-1094. – reference: Feifel D, MacDonald K, Nguyen A, Cobb P, Warlan H, Galangue B, Minassian A, Becker O, Cooper J, Perry W, Lefebvre M, Gonzales J, Hadley A (2010) Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol Psychiatry 68:678-680. – reference: Bale TL, Davis AM, Auger AP, Dorsa DM, McCarthy MM (2001) CNS region-specific oxytocin receptor expression: importance in regulation of anxiety and sex behavior. J Neurosci 21:2546-2552. – reference: Kushner MG, Abrams K, Borchardt C (2000) The relationship between anxiety disorders and alcohol use disorders: a review of major perspectives and findings. Clin Psychol Rev 20:149-171. – reference: Epperson CN, McDougle CJ, Price LH (1996) Intranasal oxytocin in obsessive-compulsive disorder. Biol Psychiatry 40:547-549. – volume: 40 start-page: 261 year: 1991 end-page: 265 article-title: Oxytocin attenuates tolerance not only to the hypothermic but also to the myorelaxant and akinesic effects of ethanol in mice publication-title: Pharmacol Biochem Behav – volume: 132 start-page: 50 year: 2011 end-page: 53 article-title: Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia publication-title: Schizophr Res – volume: 162 start-page: 1093 year: 2002 end-page: 1094 article-title: Symptom‐triggered vs. fixed‐schedule doses of benzodiazepine for alcohol withdrawal: a randomized treatment trial publication-title: Arch Intern Med – volume: 435 start-page: 673 year: 2005 end-page: 676 article-title: Oxytocin increases trust in humans publication-title: Nature – volume: 16 start-page: 319 year: 2004 end-page: 324 article-title: Anxiety and stress responses in female oxytocin deficient mice publication-title: J Neuroendocrinol – volume: 88 start-page: 127 year: 2009 end-page: 151 article-title: Oxytocin: the great facilitator of life publication-title: Prog Neurobiol – volume: 22 start-page: 71 year: 1987 end-page: 74 article-title: Effects of neurohypophyseal peptide hormones on alcohol dependence and withdrawal publication-title: Alcohol Alcohol – volume: 71 start-page: 459 year: 1988 end-page: 466 article-title: Brain monoamines are involved in mediating the action of neurohypophyseal peptide hormones on ethanol tolerance publication-title: Acta Physiol Hung – volume: 40 start-page: 547 year: 1996 end-page: 549 article-title: Intranasal oxytocin in obsessive‐compulsive disorder publication-title: Biol Psychiatry – volume: 59 start-page: 22 year: 1998 end-page: 33 article-title: The Mini‐International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM‐IV and ICD‐10 publication-title: J Clin Psychiatry – volume: 21 start-page: 2546 year: 2001 end-page: 2552 article-title: CNS region‐specific oxytocin receptor expression: importance in regulation of anxiety and sex behavior publication-title: J Neurosci – volume: 33 start-page: 1582 year: 2009 end-page: 1588 article-title: A double‐blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal publication-title: Alcohol Clin Exp Res – volume: 5 start-page: 514 year: 2002 end-page: 516 article-title: Sniffing neuropeptides: a transnasal approach to the human brain publication-title: Nat Neurosci – year: 1971 – volume: 84 start-page: 1353 year: 1989 end-page: 1357 article-title: Assessment of alcohol withdrawal: the revised Clinical Institute Withdrawal Assessment of Alcohol Scale (CIWA‐Ar) publication-title: Br J Addict – volume: 13 start-page: 1083 year: 1992 end-page: 1085 article-title: Oxytocin in obsessive compulsive disorder publication-title: Peptides – volume: 61 start-page: 731 year: 2007b end-page: 733 article-title: Oxytocin improves “mind‐reading” in humans publication-title: Biol Psychiatry – volume: 23 start-page: 945 year: 1998 end-page: 962 article-title: Oxytocin and addiction: a review publication-title: Psychoneuroendocrinology – volume: 34 start-page: 145A year: 2010 article-title: Inhibitory effects of oxytocin on anxiety‐like behavior and alcohol consumption in P‐rats subjected to repeated cycles of voluntary ethanol consumption and stress publication-title: Alcohol Clin Exp Res – volume: 144 start-page: 2291 year: 2003 end-page: 2296 article-title: Female oxytocin‐deficient mice display enhanced anxiety‐related behavior publication-title: Endocrinology – volume: 73 start-page: 97 year: 1989 end-page: 103 article-title: Intraventricular administration of neurohypophyseal hormones interferes with the development of tolerance to ethanol publication-title: Acta Physiol Hung – volume: 18 start-page: 1 year: 2010 end-page: 21 article-title: The peptide that binds: a systematic review of oxytocin and its prosocial effects in humans publication-title: Harv Rev Psychiatry – volume: 26 start-page: 497 year: 2011 end-page: 504 article-title: Anxiolytic‐like effect of oxytocin in the simulated public speaking test publication-title: J Psychopharmacol – volume: 60 start-page: 1209 year: 1996 end-page: 1215 article-title: An anxiolytic action of oxytocin is enhanced by estrogen in the mouse publication-title: Physiol Behav – volume: 31 start-page: 1473 year: 2007 end-page: 1481 article-title: Drug challenges reveal differences in mediation of stress facilitation of voluntary alcohol drinking and withdrawal‐induced anxiety in alcohol‐preferring P rats publication-title: Alcohol Clin Exp Res – volume: 13 start-page: 285 year: 1980 end-page: 290 article-title: Effects of peptides related to neurohypophyseal hormones on ethanol tolerance publication-title: Pharmacol Biochem Behav – volume: 68 start-page: 678 year: 2010 end-page: 680 article-title: Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients publication-title: Biol Psychiatry – volume: 20 start-page: 149 year: 2000 end-page: 171 article-title: The relationship between anxiety disorders and alcohol use disorders: a review of major perspectives and findings publication-title: Clin Psychol Rev – volume: 178 start-page: 367 year: 2004 end-page: 380 article-title: Stress sensitization of ethanol withdrawal‐induced reduction in social interaction: inhibition by CRF‐1 and benzodiazepine receptor antagonist and a 5‐HT1A‐receptor agonist publication-title: Neuropsychopharmacology – volume: 62 start-page: 1187 year: 2007a end-page: 1190 article-title: Oxytocin attenuates amygdala responses to emotional faces regardless of valence publication-title: Biol Psychiatry – volume: 31 start-page: 612 year: 2007 end-page: 618 article-title: Multidimensionality of the Alcohol Withdrawal Symptom Checklist: a factor analysis of the Alcohol Withdrawal Symptom Checklist and CIWA‐Ar publication-title: Alcohol Clin Exp Res – volume: 185 start-page: 218 year: 2006 end-page: 225 article-title: Anxiolytic‐like activity of oxytocin in male mice: behavioral and autonomic evidence, therapeutic implications publication-title: Psychopharmacology – volume: 25 start-page: 11489 year: 2005 end-page: 11493 article-title: Oxytocin modulates neural circuitry for social cognition and fear in humans publication-title: J Neurosci – year: 2004 – volume: 35 start-page: 83 year: 2010 end-page: 93 article-title: Effects of intranasal oxytocin on emotional face processing in women publication-title: Psychoneuroendocrinology – volume: 58 start-page: 639 year: 2008 end-page: 650 article-title: Oxytocin shapes the neural circuitry of trust and trust adaptation in humans publication-title: Neuron – volume: 81 start-page: 881 year: 1997 end-page: 907 article-title: Pharmacotherapies for alcohol abuse. Withdrawal and treatment publication-title: Med Clin North Am – volume: 81 start-page: 629 year: 2001 end-page: 683 article-title: The oxytocin receptor system: structure, function, and regulation publication-title: Physiol Rev – volume: 278 start-page: 144 year: 1997 end-page: 151 article-title: Pharmacological management of alcohol withdrawal: a meta‐analysis and evidence‐based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal publication-title: JAMA – volume: 6 start-page: 7 year: 1985 end-page: 10 article-title: The effect of oxytocin and fragment (MIF‐1) on the development of tolerance to hypothermic and hypnotic action of ethanol in the rat publication-title: Peptides – volume: 138 start-page: 2829 year: 1997 end-page: 2834 article-title: Central oxytocin administration reduces stress‐induced corticosterone release and anxiety behavior in rats publication-title: Endocrinology – volume: 107 start-page: 4389 year: 2010 end-page: 4394 article-title: Promoting social behavior with oxytocin in high‐functioning autism spectrum disorders publication-title: Proc Natl Acad Sci U S A – volume: 54 start-page: 1389 year: 2003 end-page: 1398 article-title: Social support and oxytocin interact to suppress cortisol and subjective responses to psychosocial stress publication-title: Biol Psychiatry – volume: 23 start-page: 1289 year: 1999 end-page: 1295 article-title: Psychometric properties of the Penn Alcohol Craving Scale publication-title: Alcohol Clin Exp Res – volume: 120 start-page: e9 year: 2007 article-title: Baclofen for alcohol withdrawal: not comparable to the gold standard (benzodiazepines) publication-title: Am J Med – volume: 63 start-page: 3 year: 2008 end-page: 5 article-title: Oxytocin increases gaze to the eye region of human faces publication-title: Biol Psychiatry – volume: 83 start-page: 393 year: 1988 end-page: 402 article-title: Reliability of a timeline followback method: assessing normal drinkers' reports of recent drinking and a comparative evaluation across several populations publication-title: Br J Addict – volume: 2 start-page: 567 year: 1985 end-page: 574 article-title: The effects of neurohypophyseal hormones on tolerance to the hypothermic effect of ethanol publication-title: Alcohol – ident: e_1_2_6_9_1 doi: 10.1001/archinte.162.10.1117 – ident: e_1_2_6_39_1 doi: 10.1016/j.amjmed.2006.03.015 – volume: 34 start-page: 145A year: 2010 ident: e_1_2_6_21_1 article-title: Inhibitory effects of oxytocin on anxiety‐like behavior and alcohol consumption in P‐rats subjected to repeated cycles of voluntary ethanol consumption and stress publication-title: Alcohol Clin Exp Res – ident: e_1_2_6_36_1 doi: 10.1016/0196-9781(85)90067-1 – ident: e_1_2_6_49_1 doi: 10.1210/endo.138.7.5255 – volume: 71 start-page: 459 year: 1988 ident: e_1_2_6_46_1 article-title: Brain monoamines are involved in mediating the action of neurohypophyseal peptide hormones on ethanol tolerance publication-title: Acta Physiol Hung – ident: e_1_2_6_5_1 doi: 10.1016/j.neuron.2008.04.009 – ident: e_1_2_6_11_1 doi: 10.1016/j.biopsych.2006.07.015 – ident: e_1_2_6_19_1 doi: 10.1016/0091-3057(91)90549-H – ident: e_1_2_6_24_1 doi: 10.1016/S0272-7358(99)00027-6 – ident: e_1_2_6_22_1 doi: 10.1038/nature03701 – ident: e_1_2_6_23_1 doi: 10.1016/S0306-4530(98)00064-X – ident: e_1_2_6_33_1 doi: 10.1111/j.1530-0277.2007.00445.x – ident: e_1_2_6_29_1 doi: 10.1016/S0031-9384(96)00212-0 – ident: e_1_2_6_42_1 doi: 10.1111/j.1360-0443.1988.tb00485.x – ident: e_1_2_6_16_1 doi: 10.1152/physrev.2001.81.2.629 – ident: e_1_2_6_14_1 doi: 10.1016/j.biopsych.2010.04.039 – ident: e_1_2_6_3_1 doi: 10.1073/pnas.0910249107 – volume-title: EDITS Manual for the Profile of Mood States year: 1971 ident: e_1_2_6_30_1 – ident: e_1_2_6_35_1 doi: 10.1111/j.1530-0277.2007.00345.x – ident: e_1_2_6_40_1 doi: 10.1016/S0025-7125(05)70554-X – ident: e_1_2_6_7_1 doi: 10.1038/nn0602-849 – ident: e_1_2_6_27_1 doi: 10.1210/en.2002-0197 – ident: e_1_2_6_15_1 doi: 10.1111/j.1530-0277.1999.tb04349.x – volume: 59 start-page: 22 year: 1998 ident: e_1_2_6_41_1 article-title: The Mini‐International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM‐IV and ICD‐10 publication-title: J Clin Psychiatry – ident: e_1_2_6_26_1 doi: 10.3109/10673220903523615 – ident: e_1_2_6_43_1 doi: 10.1111/j.1360-0443.1989.tb00737.x – ident: e_1_2_6_12_1 doi: 10.1016/j.psyneuen.2009.06.016 – volume: 178 start-page: 367 year: 2004 ident: e_1_2_6_8_1 article-title: Stress sensitization of ethanol withdrawal‐induced reduction in social interaction: inhibition by CRF‐1 and benzodiazepine receptor antagonist and a 5‐HT1A‐receptor agonist publication-title: Neuropsychopharmacology – ident: e_1_2_6_34_1 doi: 10.1016/j.schres.2011.07.027 – ident: e_1_2_6_38_1 doi: 10.1007/s00213-005-0293-z – ident: e_1_2_6_44_1 doi: 10.1016/0741-8329(85)90082-5 – ident: e_1_2_6_31_1 doi: 10.1111/j.1530-0277.2009.00986.x – ident: e_1_2_6_6_1 doi: 10.1016/0196-9781(92)90010-Z – volume: 22 start-page: 71 year: 1987 ident: e_1_2_6_45_1 article-title: Effects of neurohypophyseal peptide hormones on alcohol dependence and withdrawal publication-title: Alcohol Alcohol – ident: e_1_2_6_17_1 doi: 10.1016/j.biopsych.2007.06.026 – ident: e_1_2_6_37_1 doi: 10.1016/S0091-3057(80)80043-8 – ident: e_1_2_6_13_1 doi: 10.1016/0006-3223(96)00120-5 – volume: 88 start-page: 127 year: 2009 ident: e_1_2_6_25_1 article-title: Oxytocin: the great facilitator of life publication-title: Prog Neurobiol – volume: 73 start-page: 97 year: 1989 ident: e_1_2_6_47_1 article-title: Intraventricular administration of neurohypophyseal hormones interferes with the development of tolerance to ethanol publication-title: Acta Physiol Hung – volume-title: Neuroadaptation to alcohol and morphine is altered in oxytocin knockout mice year: 2004 ident: e_1_2_6_48_1 – ident: e_1_2_6_2_1 doi: 10.1111/j.0953-8194.2004.01161.x – ident: e_1_2_6_18_1 doi: 10.1016/S0006-3223(03)00465-7 – ident: e_1_2_6_4_1 doi: 10.1523/JNEUROSCI.21-07-02546.2001 – ident: e_1_2_6_10_1 doi: 10.1016/j.biopsych.2007.03.025 – ident: e_1_2_6_32_1 doi: 10.1177/0269881111400642 – ident: e_1_2_6_20_1 doi: 10.1523/JNEUROSCI.3984-05.2005 – ident: e_1_2_6_28_1 doi: 10.1001/jama.1997.03550020076042 – reference: 23614612 - Alcohol Clin Exp Res. 2013 May;37(5):720-1 |
| SSID | ssj0004866 |
| Score | 2.4806588 |
| Snippet | Background
The neuropeptide, oxytocin (OT), has been reported to block tolerance formation to alcohol and decrease withdrawal symptoms in alcohol‐dependent... The neuropeptide, oxytocin (OT), has been reported to block tolerance formation to alcohol and decrease withdrawal symptoms in alcohol-dependent rodents.... |
| SourceID | pubmedcentral proquest pubmed crossref wiley istex |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 484 |
| SubjectTerms | Administration, Intranasal Adult Alcohol Withdrawal Alcoholism - drug therapy Alcoholism - epidemiology Alcoholism - psychology Dependence Detoxification Double-Blind Method Female Human Subjects Humans Male Middle Aged Oxytocin Oxytocin - administration & dosage Pilot Projects Substance Withdrawal Syndrome - epidemiology Substance Withdrawal Syndrome - prevention & control Substance Withdrawal Syndrome - psychology Tolerance |
| Title | Intranasal Oxytocin Blocks Alcohol Withdrawal in Human Subjects |
| URI | https://api.istex.fr/ark:/67375/WNG-6C8R956P-K/fulltext.pdf https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1530-0277.2012.01958.x https://www.ncbi.nlm.nih.gov/pubmed/23025690 https://www.proquest.com/docview/1314336717 https://pubmed.ncbi.nlm.nih.gov/PMC3557665 |
| Volume | 37 |
| WOSCitedRecordID | wos000315500600015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVWIB databaseName: Wiley Online Library Full Collection 2020 customDbUrl: eissn: 1530-0277 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0004866 issn: 0145-6008 databaseCode: DRFUL dateStart: 19970101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrR1db9Mw8AQtD7xsfNMxJiOhvWVK4vgjT6iUFRCoTBVT-2bZiatVndIp6aD8e85OGhaxhwkh5cGKfZZ9vvOdfec7gLco01KbMRbEmtogYZEOtDAxllKaSpSY3Cx8sgkxmcj5PD1r_J_cW5g6PkR74eY4w-_XjsG1qbpMzmjobZDOQys-cU_f5Anqk_0YyTjpQf_DdHz-9c8rSVlbLqOEBSjmZdev59a-OsKq7_C-vU0T_duh8qai6yXVeP9_zvER7DX6KhnWBPYY7tniCRzWj3rJzF4udGnJMdn9WJerp_DusxtfoSv88237a4N1BXmPUnNVkWGdkpfMlpuLvNQ_sQlWelMCwU3M3QpVz-B8fPp99CloEjUEGUsi3DCNzqW04ULmVORCJiwWLMOllllImRFWSyNCYaTN-QI_yXjGZMaFjXORJ4w-h16xLuxLIDZklhlqYq0t6nYuep-39WZ47OQi5wMQuxVRWRPF3CXTuFQ3TjOIM-VwphzOlMeZ2g4gaiGv6kged4A59oveAuhy5TzhBFOzyUfFR3KK58sz9WUAb3ZUoZA_ndFFF3Z9XamIokZKOQ5_AC9qKml7w-MfapxpiJPq0E_bwMX-7tYUywsfAxzVRME5Q0hPP3eekRqOTqeuePDPkK_gYexzgjhHvEPobcpr-xoeZD82y6o8gvtiLo8a3vsNIkYoMA |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrR1da9swUIxksL2s3Xe6dtNg9M3FX_rw00jTZi3NshJa0jchywoNKc6w0y3797uTHa9mfShj4Adh6YR0utOddKc7Qj6BTEusYcwLdWS9mAXa0yINoZREiQSJydOZSzYhxmN5dZWc1-mA8C1MFR-iuXBDznD7NTI4Xki3uZxFvjNCootWeIBv3-QBKJTdGKiKdUj3aDK8HP15Jikr02UQMw_kvGw79tzbV0tadRHx6_tU0b89Ku9quk5UDbf-6yS3ybNaY6X9isSek0c2f0F2q2e9dGpvZrqwdJ9ufiyLxUvy-RQHmOsS_nxb_1pBXU4PQW4uStqvkvLS6Xx1nRX6JzSBSmdMoLCN4b1Q-YpcDo8vBidenarBMywOYMtMdSal9Wcyi0QmZMxCwQwstjR-xFJhtUyFL1JpMz6DTzJumDRc2DATWcyi16STL3P7llDrM8vSKA21tqDdYfw-Z-01cPDkIuM9IjZLokwdxxzTadyoO-cZwJlCnCnEmXI4U-seCRrI71UsjwfA7LtVbwB0sUBfOMHUdPxF8YGcwAnzXJ31yMcNWSjgUDS76Nwub0sVRKCTRhyG3yNvKjJpeoMDIOiciQ-TahFQ0wCjf7dr8vm1iwIOiqLgnAGkI6AHz0j1B8cTLO78M-QH8uTk4utIjU7HZ-_I09BlCEG3vF3SWRW3do88Nj9W87J4X7Pgb_FnKzg |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrR1da9swUIxmjL3se122ttNg9M3FtqwPP40sbbbSkoWwkr4JWZJpSHGKnW7Zv99Jdtya9qGMgR-M5bOl053uTne6Q-gzyLTUakqDWBEbJDRSgeJZDHcpSQVITJblvtgEH4_F-Xk6acoBubMwdX6IdsPNcYZfrx2D2yuTd7mcktA7IV2IVnzgzr6JA1Aoe_AnBlzaO5yOzk5vjkmK2nUZJTQAOS-6gT33fqsjrXoO8ev7VNG7EZW3NV0vqkbP_-sgX6BnjcaKBzWJvUSPbPEK7dTHevHMXuaqtHgfbx4sy8Vr9OXYdbBQFTz5sf6zgrYCfwW5uajwoC7Ki2fz1YUp1W94BRq9MwHDMub2hao36Gx09HP4PWhKNQSaJhEsmZkyQtgwF4Zww0VCY041TLbQIaEZt0pkPOSZsIblcAnKNBWacRsbbhJK3qKtYlnYdwjbkFqakSxWyoJ25_L3eW-vBsOTccP6iG-mROomj7krp3Epb9kzgDPpcCYdzqTHmVz3UdRCXtW5PB4As-9nvQVQ5cLFwnEqZ-Nvkg3FFCzMiTzpo08bspDAoc7togq7vK5kREAnJQy630fbNZm0XwMDEHTONIRBdQiofcFl_-62FPMLnwUcFEXOGAVIT0APHpEcDI-m7vb9P0N-RE8mhyN5ejw--YCexr5AiIvK20Fbq_La7qLH-tdqXpV7DQf-BTqeKrM |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Intranasal+oxytocin+blocks+alcohol+withdrawal+in+human+subjects&rft.jtitle=Alcoholism%2C+clinical+and+experimental+research&rft.au=Pedersen%2C+Cort+A&rft.au=Smedley%2C+Kelly+L&rft.au=Leserman%2C+Jane&rft.au=Jarskog%2C+Lars+Fredrik&rft.date=2013-03-01&rft.issn=1530-0277&rft.eissn=1530-0277&rft.volume=37&rft.issue=3&rft.spage=484&rft_id=info:doi/10.1111%2Fj.1530-0277.2012.01958.x&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0145-6008&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0145-6008&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0145-6008&client=summon |